Rebeca Sicilia Torres1, C. Cabrera1, C. Casanova1, F. Le?n1,
G. Juli?1, J. Mar?n1, P. De Torres1, M.A.
Garc?a1, M. Divo1 and B. Celli1
Hospital Universitario Doctor Negr?n, Las Palmas de Gran
Canaria, Spain, 2Pneumology, Hospital Universitario Doctor
Negr?n, Las Palmas de Gran Canaria, Spain, 3Pneumology,
Hospital Universitario Virgen de la Candelaria, Santa Cruz de Tenerife,
Spain, 4Pneumology, Hospital Universitario Doctor Negr?n,
Las Palmas de Gran Canaria, Spain, 5Pneumology, Hospital Universitario
Doctor Negr?n, Las Palmas de Gran Canaria, Spain,
6Pneumology, Hospital Universitario Miguel Servet, Zaragoza, Spain,
7Pneumology, Cl?nica Universitaria de Navarra, Navarra,
Spain, 8Statistics, Hospital Universitario Doctor Negr?n,
Las Palmas de Gran Canaria, Spain, 9Pulmonary and Critical Care
Division, Brigham and Women's Hospital, Boston, United States,
10Pulmonary and Critical Care Division, Brigham and Women's Hospital,
Boston, United States
Little is known about anxiety and depression and their impact among
never-smokers COPD patients. The aim of our study was to assess the
prevalence of these disorders and their effect on the quality of life
and clinical parameters.
We carried out a cross-sectional study in two terciary hospitals. The
presence of anxiety and depression was assessed using the Hospital
Anxiety and Depression (HAD) scale. The COPD Assessment Test (CAT) was
used to evaluate quality of life. The BODE and COTE (COPD specific
comorbidity test) indexes were also calculated. The clinical parameters
included were dyspnea measured by the modified Medical Research Council
scale (mMRC), six minutes walking test (6MWT), exacerbations and body
mass index (BMI).
We enrolled 260 patients, 180 smokers and 80 never-smokers. There were
no significant differences in age, gender, forced expiratory volumen in
one second (FEV1%) and dyspnea (mMRC).
The prevalence of anxiety (A) and depression (D) was higher in smokers
than in never smokers (A: 66.9% vs. 34.6%, p<0.001; D: 30.2% vs.
20.5%, p=0.174), as well as the CAT score (15 vs. 12.6, p=0.70). The
presence of anxiety and depression in never-smokers was significantly
associated with less distance walked and more dyspnea at the end of the
6MWT, more exacerbations and higher scores in the CAT, BODE and COTE
indexes. Only 40% of anxious and depressed never-smoker patients had
The prevalence of anxiety and depression is lower in never-smokers.
These disorders are clearly influenced by clinical parameters in this
Image : https://www.practicalpainmanagement.com/sites/...